Pluvicto presents a much lower risk of radiation damage to healthy cells, because it is not a beam, but a molecule that targets only cells that express PSMA. Here is an excerpt from the Mayo entry about Pluvicto:

Treatments that target PSMA: Radiopharmaceutical treatments can target a protein that's common on prostate cancer cells called prostate-specific membrane antigen. It's also called PSMA. One radiopharmaceutical medicine that works in this way is lutetium Lu-177 vipivotide tetraxetan (Pluvicto). This medicine contains a molecule that finds and sticks to the PSMA on prostate cancer cells. The medicine also contains a radioactive substance. A healthcare professional gives this medicine through a vein. The medicine finds the prostate cancer cells and releases the radiation directly into the cells. It can treat prostate cancer anywhere in the body. PSMA therapy only works if the prostate cancer cells have the PSMA protein. Side effects include dry mouth, dry eyes, nausea and feeling very tired.